Skip to Main Content
Contribute Try STAT+ Today
Trending:
Coronavirus
Biotech
First Opinion
Health

Latest

Delivering must-read stories about health, medicine, and scientific discovery

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Artificial intelligence
Biotech

Stoke Therapeutics drug, targeting genetic cause of childhood epilepsy, reduces seizure activity

By Adam Feuerstein

Pharmalot

Pharmalittle: FDA plans rapid review of Omicron vaccines and drugs; Califf would keep Woodcock at FDA

By Ed Silverman

health inequity
First Opinion

In defense of not treating everyone the same

By Ian Tong

research funding, medical devices
First Opinion

Reforms needed for FDA’s regulation of medical devices

By Kushal Kadakia and Harlan M. Krumholz

In the Lab

We’ll know more soon about Omicron. Here’s how to interpret the coming flood of data

By Andrew Joseph

US Covid Surveillance
Health

‘Just stupid stuff’: Logistics and lack of testing stymied finding the Omicron variant in the U.S.

By Megan Molteni

antiviral
Pharmalot

Former Immunomedics executives are charged with insider trading

By Ed Silverman

J WOODCOCK
Politics

Califf, nominee to lead FDA, asks Woodcock to stay in leadership role if he’s confirmed

By Nicholas Florko

Health Tech

Virtual care companies rush to ease access to Covid-19 antivirals

By Katie Palmer

The Readout LOUD

Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

By Damian Garde, Meg Tirrell and Adam Feuerstein

Capitol reflection public health
Politics

Hospitals and doctors fail to stop end-of-year Medicare cuts, for now

By Rachel Cohrs

Health

Second U.S. case of Omicron variant indicates domestic transmission

By Andrew Joseph

In the Lab

Most advanced lab-grown human embryos prompt a pressing question: Are they getting too real?

By Megan Molteni

AI race
Health Tech

Docs pitch the C-suite on tech & why telehealth pricing matters

By Mario Aguilar and Isabella Cueto

Pharmalot

Pharmalittle: Glaxo and Vir drug appears to work against Omicron; employees sue Bristol Myers over vaccine mandate

By Ed Silverman

Joe Biden close-up
Politics

Biden’s new Covid plan: more boosters, free home testing, and ‘monoclonal antibody strike teams’

By Nicholas Florko

First Opinion

The Fifth Circuit Court got the science wrong on OSHA’s vaccination mandate

By Jeffrey E. Harris

doc office illo
First Opinion

Another fight for Covid long-haulers: having their pain acknowledged

By Kate M. Nicholson

Radiologists supervise MRI
Health Tech

Artificial intelligence is making a pitch to transform radiology. Will it pay off for hospitals?

By Katie Palmer

Health

Some experts suggest Omicron variant may have evolved in an animal host

By Helen Branswell

Blood test droplet
In the Lab

Liquid biopsies could help screen for countless cancers. But who should get them?

By Angus Chen

medication overload
Pharmalot

Amgen joins a growing list of drug makers cutting discounts to safety-net hospitals

By Ed Silverman

SARS-CoV-2 virus particle
Health

First case of Omicron coronavirus variant identified in the U.S.

By Andrew Joseph

Pharmalot

Pharmalittle: Merck Covid pill squeaks past FDA panel; analysis explores whether insurers give ‘fair access’ to drugs

By Ed Silverman

red & yellow pill chart drug price controls
Pharmalot

Just how many barriers do health insurers create to fair access to medicines?

By Ed Silverman

Vertex Pharmaceuticals - sunset
Biotech

In a medical first, Vertex drug successfully targets the underlying cause of a genetic kidney disease

By Adam Feuerstein

Stock exchange
Pharmalot

Socially responsible investor coalitions push greater access to medicines in shareholder proposals

By Ed Silverman

First Opinion Podcast
Play
First Opinion Podcast

Listen: Who owns your health data — and why you should care

By Patrick Skerrett